Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
October 16, 2023 Advances AI-Driven Programmable Drug Treatment Amidst Adversity

Israel, biotech trailblazer pushes forward with its groundbreaking programmable drug treatment solution

In the face of recent turmoil in Israel, biotech innovator remains resolute in its mission to revolutionize drug treatments with AI. The startup is set to launch its cutting-edge programmable drug solution, even as the nation weathers challenging times. This groundbreaking technology leverages AI to design lipid nanoparticles (LNPs), a crucial element in creating programmable drug therapies.

As CEO Yogev Debbi explains,'s breakthrough platform integrates experimental techniques and machine learning to develop advanced delivery formulations. These innovations aim to unlock the potential of nucleic acid-based and genetic medicines. The core of their solution revolves around RNA-based therapies, holding promise for treating infectious diseases, various cancers, and single-gene disorders. However, RNA molecules are inherently fragile, requiring specialized protection to survive the journey to their intended targets within the body. This is where Mana steps in, crafting the essential protective "package" for these delicate RNA molecules.'s momentous debut from stealth mode is accompanied by a substantial $19.5 million seed investment led by notable backers such as Andreessen Horowitz Bio + Health, Base4 Capital, NFX, LionBird, and Technion. This significant funding underscores the industry's recognition of the startup's pioneering work in drug discovery.

CEO Debbi had been preparing to present his company's groundbreaking approach to drug discovery at two conferences in San Diego when the recent attacks unfolded in Israel. The decision to move forward in the midst of these unprecedented challenges was not taken lightly.

He emphasized, "We stayed committed to our goals, to our partners, and to patients who could eventually benefit from this approach because we're working in drug development." The determination to progress during such trying times is a testament to the company's dedication to advancing medicine and improving lives.

Launching a startup is always a formidable task, but forging ahead during wartime conditions exemplifies unwavering commitment. Despite the ongoing adversity, remains steadfast in its pursuit of groundbreaking advancements in biotech, sending a powerful message of resilience to its team, its country, and the world.

Neil Hodgson Coyle
Neil Hodgson-Coyle
Editorial chief at TechNews180
Back to top

Related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram